太極集團:乙酰氨基酚片通過仿製藥一致性評價
格隆匯2月10日丨太極集團(600129.SH)公佈,近日,公司控股子公司西南藥業股份有限公司(以下簡稱:西南藥業)收到國家藥品監督管理局關於對乙酰氨基酚片的《藥品補充申請批件》,批件號為2020B02183。根據上海證券交易所《上市公司行業信息披露指引第七號—醫藥製造》的相關要求。
對乙酰氨基酚片用於普通感冒或流行性感冒引起的發熱,也用於緩解輕至中度疼痛如頭痛、關節痛、偏頭痛、牙痛、肌肉痛、神經痛、痛經。
2019年1月,西南藥業向國家藥監局提交了該品種一致性評價申請,現已獲得《藥品補充申請批件》。截止目前,西南藥業對該產品累計投入研發費用355萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.